YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.54 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.91 per share a year ago. These figures are adjusted for non-recurring items. A…
Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items. T…
(RTTNews) - Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as in…
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84. This compares to a loss of $3.2 per share a year ago. These figures are adjusted for non-recurring i…
(RTTNews) - Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyrizon, and Sol-Gel were also some of the…
US equity indexes fell on Tuesday as oil prices continued to rise amid uncertainty surrounding truce PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
(RTTNews) - Sol-Gel Technologies Ltd. (SLGL) announced the pricing of an oversubscribed underwritten public offering, underscoring strong investor interest in its dermatology-focused pipeline. The company stated that net proceeds will be u…
[FDA approved concept. Rubber stamp with FDA and medicine.] Bet_Noire/iStock via Getty Images * Sol‑Gel Technologies (SLGL [https://seekingalpha.com/symbol/SLGL]) priced [https://seekingalpha.com/pr/20447935-sol-gel-technologies-ltd-announ…
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a price of $72.00 per Shar…
Sol-Gel Technologies (SLGL) is a clinical-stage dermatology company focused on topical drugs for skin diseases. SLGL demonstrates exceptional technical momentum and is up 1,310% over the past 52 weeks. The stock set a new three-year high e…
Sol-Gel Technologies Ltd. Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In September 2025, Sol-Gel an…
Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada appro…
(RTTNews) - Sol-Gel Technologies Ltd. (SLGL) has notched a major regulatory win with Health Canada's approval of EPSOLAY, a topical cream for the treatment of inflammatory lesions of rosacea in adults. The Notice of Compliance or NOC, issu…
* Sol-Gel Technologies (NASDAQ:SLGL [https://seekingalpha.com/symbol/SLGL]) said on Thursday that Health Canada has issued [https://seekingalpha.com/pr/20220823-sol-gel-announces-health-canada-approval-of-epsolay] a Notice of Compliance fo…
Investing.com - Sol Gel Tech (NASDAQ: SLGL) reported second quarter EPS of $4.1700, $4.84 better than the analyst estimate of $-0.6700. Revenue for the quarter came in at $17.26M versus the consensus estimate of $2.86M. Sol Gel Tech’s stoc…
* Sol-Gel Technologies press release [https://seekingalpha.com/pr/20202388-sol-gel-reports-second-quarter-2025-financial-results-and-provides-corporate-updates] (NASDAQ:SLGL [https://seekingalpha.com/symbol/SLGL]): Q2 GAAP EPS of -$1.57. *…
Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease…
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the F…
Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results a…
SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in Gorlin syndromeSol-Gel to host a virtual…
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NE…
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains cash runway into the second half of 2025…
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two…
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will provide up to $11 million in upfront payments…
Key Insights Sol-Gel Technologies' significant insider ownership suggests inherent interests in company's expansion Moshe Arkin owns 51% of the company 27% of Sol-Gel Technologies is held by Institutions Every investor in Sol-Gel Technolog…
Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to high-teens Non-dilutive capital strengthens Sol-Gel’s balanc…
Sol-Gel Technologies Ltd. Sol-Gel to receive up to $11 millionin upfront payments and regulatory and sales milestonesfor both drugs, combined, plus additional royalties ranging from low double-digits to high-teens Non-dilutive capital stre…
Sol-Gel to receive up to $11 millionin upfront payments and regulatory and sales milestonesfor both drugs, combined, plus additional royalties ranging from low double-digits to high-teensNon-dilutive capital strengthens Sol-Gel’sbalance sh…
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can avoid big losses. Zooming in on an example, the Sol-Gel Technologies Ltd. (NASDAQ:SLGL) share price dropped 60% in the las…
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring it…
Sol-Gel Technologies Ltd. Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib)for Gorli…
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib)for Gorlin syndrome into Phase 3 te…
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since…
The last few weeks have been rocky, with the collapse of Silicon Valley Bank, and the crypto-heavy Silvergate and Signature banks, dominating the headlines. For a short time, it seemed that the contagion would spread to the global financia…
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced tha…
Sol-Gel Technologies Ltd. NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pip…